CARVIVIB 6.25 CARVEDILOL 6.25mg. IP

Carvivib 6.25 tablets contain Carvedilol 6.25 mg and are used for high blood pressure and heart failure. Main uses: management of essential hypertension; treatment of mild to severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors and digitalis; reduction of cardiovascular mortality in clinically stable patients with left ventricular ejection fraction of 40% or less following myocardial infarction; can be used alone or with other antihypertensive agents, especially thiazide-type diuretics.

Common side effects of Carvivib 6.25 Tablet include dizziness; fatigue and weakness; low blood pressure (hypotension); diarrhoea; high blood sugar (hyperglycaemia); slow heart rate (bradycardia). Get medical help at once if you notice bronchospasm or status asthmaticus in susceptible patients; worsening heart failure and fluid retention; severe low blood pressure or very slow heart rate.

Each Carvivib 6.25 tablet contains Carvedilol 6.25 mg. The right dose and how long to take it depend on the condition, age and other medicines, so use Carvivib 6.25 Tablet only as your doctor advises.

The MRP of Carvivib 6.25 Tablet is ₹60 for a pack of 10x10 (Blister). For chemists and distributors, the PTR is ₹45.71 and the PTS is ₹41.14.

Each Carvivib 6.25 tablet contains Carvedilol 6.25 mg. It comes in a pack of 10x10 (Blister).

Carvedilol in Carvivib 6.25 blocks beta-adrenergic receptors, so the heart beats more slowly and with less force, which reduces its workload. At the same time it blocks alpha-1 adrenergic receptors, helping blood vessels relax so blood pressure comes down. It has no intrinsic sympathomimetic activity.

Must not be used by patients with bronchial asthma or related bronchospastic conditions. Must not be used with second- or third-degree AV block, sick sinus syndrome, or severe bradycardia (unless a permanent pacemaker is in place). Must not be used in cardiogenic shock or decompensated heart failure requiring intravenous inotropic therapy. Must not be used in severe hepatic impairment, or with a history of serious hypersensitivity to carvedilol, any component of the medicine, or other medicines containing carvedilol. Check with a doctor first if you have diabetes (it may mask low blood sugar symptoms) or non-allergic bronchospasm such as chronic bronchitis or emphysema (beta-blockers should be avoided, but if deemed necessary, use with caution at the lowest effective dose); do not stop the medicine suddenly, discontinuation should be supervised.

Carvivib 6.25 Tablet is a brand of Vibcare Pharma, sold through its Cure division. It is available for PCD pharma franchise and distribution in India; use the Send Enquiry or WhatsApp button on this page to ask about availability and terms.